Alaunos Therapeutics (TCRT) Current Deferred Revenue (2009 - 2018)

Alaunos Therapeutics has reported Current Deferred Revenue for 10 years, with the latest figure at $13000.0 in Q4 2018.

• For the quarter ending Q4 2018, Current Deferred Revenue fell 90.78% year-over-year to $13000.0; the trailing twelve-month figure through Dec 2018 stood at $13000.0 (down 90.78% YoY), and the FY2018 full-year result was $13000.0, down 90.78% from the prior year.
• Current Deferred Revenue for Q4 2018 stood at $13000.0, down from $49.5 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $49.5 million in Q3 2018, with the low at $13000.0 in Q4 2018.
• Historically, Current Deferred Revenue has averaged $4.5 million across 5 years, with a median of $347000.0 in 2015.
• Annual changes were most pronounced in 2014 — Current Deferred Revenue surged 3603.17% — and 2018, when it sank 98.4%.
• Alaunos Therapeutics' Current Deferred Revenue stood at $1.4 million in 2014, then surged by 404.49% to $6.9 million in 2015, then decreased by 6.88% to $6.4 million in 2016, then slumped by 97.79% to $141000.0 in 2017, then sank by 90.78% to $13000.0 in 2018.
• The last three Current Deferred Revenue figures came in at $13000.0 (Q4 2018), $49.5 million (Q3 2018), and $63000.0 (Q2 2018), per Business Quant data.